ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerAlessandra Gennari, Nadia Harbeck, Fabrice André et al.|Annals of Oncology|2021Cited by 1.4k
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast CancerAditya Bardia, Kevin Kalinsky, Ingrid A. Mayer et al.|New England Journal of Medicine|2019Cited by 846
HER2-Low Breast Cancer: Pathological and Clinical LandscapePaolo Tarantino, Giuseppe Curigliano, Erika Hamilton et al.|Journal of Clinical Oncology|2020Cited by 801
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast CancerAditya Bardia, Linda T. Vahdat, Ingrid A. Mayer et al.|Journal of Clinical Oncology|2017Cited by 407
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancerAditya Bardia, Sara A. Hurvitz, Sara M. Tolaney et al.|Annals of Oncology|2021Cited by 294